These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24098102)

  • 21. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.
    Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S
    Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Mycobacterium tuberculosis drugome and its polypharmacological implications.
    Kinnings SL; Xie L; Fung KH; Jackson RM; Xie L; Bourne PE
    PLoS Comput Biol; 2010 Nov; 6(11):e1000976. PubMed ID: 21079673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis.
    Prabu A; Hassan S; Prabuseenivasan ; Shainaba AS; Hanna LE; Kumar V
    J Mol Graph Model; 2015 Sep; 61():133-40. PubMed ID: 26245695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F; Ventura C; Santos S; Viveiros M
    Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
    Lokesh BVS; Prasad YR; Shaik AB
    Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting essential cell wall lipase Rv3802c for potential therapeutics against tuberculosis.
    Saravanan P; Avinash H; Dubey VK; Patra S
    J Mol Graph Model; 2012 Sep; 38():235-42. PubMed ID: 23085165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.
    Esposito M; Szadocka S; Degiacomi G; Orena BS; Mori G; Piano V; Boldrin F; Zemanová J; Huszár S; Barros D; Ekins S; Lelièvre J; Manganelli R; Mattevi A; Pasca MR; Riccardi G; Ballell L; Mikušová K; Chiarelli LR
    ACS Infect Dis; 2017 Jun; 3(6):428-437. PubMed ID: 28475832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
    Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
    Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NU-6027 Inhibits Growth of Mycobacterium tuberculosis by Targeting Protein Kinase D and Protein Kinase G.
    Kidwai S; Bouzeyen R; Chakraborti S; Khare N; Das S; Priya Gosain T; Behura A; Meena CL; Dhiman R; Essafi M; Bajaj A; Saini DK; Srinivasan N; Mahajan D; Singh R
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
    Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
    Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling the interactions of herbal drugs to beta-ketoacyl ACP synthase of Mycobacterium tuberculosis H37Rv.
    Ramesh KV; Purohit M; Mekhala K; Krishnan M; Wagle K; Deshmukh S
    J Biomol Struct Dyn; 2008 Apr; 25(5):481-93. PubMed ID: 18282003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.
    Rebollo-Lopez MJ; Lelièvre J; Alvarez-Gomez D; Castro-Pichel J; Martínez-Jiménez F; Papadatos G; Kumar V; Colmenarejo G; Mugumbate G; Hurle M; Barroso V; Young RJ; Martinez-Hoyos M; González del Río R; Bates RH; Lopez-Roman EM; Mendoza-Losana A; Brown JR; Alvarez-Ruiz E; Marti-Renom MA; Overington JP; Cammack N; Ballell L; Barros-Aguire D
    PLoS One; 2015; 10(12):e0142293. PubMed ID: 26642067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screen.
    Scheich C; Szabadka Z; Vértessy B; Pütter V; Grolmusz V; Schade M
    PLoS One; 2011; 6(12):e28428. PubMed ID: 22164290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel peptidomimetic peptide deformylase (PDF) inhibitors of Mycobacterium tuberculosis.
    Gokhale KM; Telvekar VN
    Chem Biol Drug Des; 2021 Jan; 97(1):148-156. PubMed ID: 32745362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular modeling studies of Fatty acyl-CoA synthetase (FadD13) from Mycobacterium tuberculosis--a potential target for the development of antitubercular drugs.
    Jatana N; Jangid S; Khare G; Tyagi AK; Latha N
    J Mol Model; 2011 Feb; 17(2):301-13. PubMed ID: 20454815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
    Kumar M; Vijayakrishnan R; Subba Rao G
    Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting type VII/ESX secretion systems for development of novel antimycobacterial drugs.
    Bottai D; Serafini A; Cascioferro A; Brosch R; Manganelli R
    Curr Pharm Des; 2014; 20(27):4346-56. PubMed ID: 24245757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.